electroCore to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC
ROCKAWAY, N.J., June 14, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic…
ROCKAWAY, N.J., June 14, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic…
YAVNE, Israel, June 14, 2023 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical…
YAVNE, Israel, June 14, 2023 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical…
DUBLIN, Ireland, June 14, 2023 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company…
DUBLIN, Ireland, June 14, 2023 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company…
DOYLESTOWN, Pa., June 14, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the…
DOYLESTOWN, Pa., June 14, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the…
225 patients now randomized in global Phase 3 clinical trial for IO102-IO103, in combination with…
225 patients now randomized in global Phase 3 clinical trial for IO102-IO103, in combination with…
SOUTH SAN FRANCISCO, Calif., June 14, 2023 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO),…
SOUTH SAN FRANCISCO, Calif., June 14, 2023 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO),…
BOSTON, June 14, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
BOSTON, June 14, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
14 patients in the immune checkpoint inhibitor naïve arm of VERSATILE-002 have experienced either a…
14 patients in the immune checkpoint inhibitor naïve arm of VERSATILE-002 have experienced either a…
Expects Extraction and Production Facility to be Operational Before the End of the Third Quarter…
Expects Extraction and Production Facility to be Operational Before the End of the Third Quarter…
ASD-101 protocol submitted to SAHPRA, South Africa’s regulatory agency PAX-101 internally developed supply chain entering…
ASD-101 protocol submitted to SAHPRA, South Africa’s regulatory agency PAX-101 internally developed supply chain entering…
Revenue increased 9% to $11.7 million for the period ended March 31, 2023 (“Q4 FY2023”)…